Mutant enterotoxin effective as a non-toxic oral adjuvant

Details Mutant enterotoxin effective as a non-toxic oral adjuvant Mutant enterotoxin effective as a non-toxic oral adjuvant

1994-08-26

2000-02-01

Housel, James C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

4241841, 4242001, 4242081, 4242341, 4242351, 4242401, 4242411, 4242611, 435 914, 4351721, A61K 3900, A61K 3938, A61K 3902, C12N 1564

Patent

active

060199822

ABSTRACT:
Methods and compositions are provided herein for the use of a novel mutant form of E. coli heat-labile enterotoxin which has lost its toxicity but has retained its immunologic activity. This enterotoxin is used in combination with an unrelated antigen to achieve an increased immune response to said antigen when administered as part of an oral vaccine preparation.

REFERENCES:
patent: 5182109 (1993-01-01), Tamura et al.
Douce et al., 1995, "Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltranferase activity act as nontoxic, mucosal adjuvants", Proc Natl Acad Sci 92:1644-1648.
Lobet et al., 1991, "Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin", Infection and Immunity 59(9):2870-2879.
Burnette et al., 1991, "Site-specific mutagenesis of the catalytic subunit of cholera toxin: Substituting lysine for arginine 7 causes loss of activity", Infection and Immunity 59(11):4266-4270.
Okamoto et al., 1988, "Effect of substitution of glycine for arginine at position 146 of the A1 subunit on biological activity of Escherichia coli heat-labile enterotoxin", J Bacteriol 170(5):2208-2211.
Hase et al., 1994, "Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs", Infect. Immun. 62(8):3051-3057.
McGhee et al., 1994, "Vaccines for mucosal immunity: Unique delivery system and immune response analyses for TH1/TH2 cells and IgE/IgA B cells", Mucosal Immunology Update, Spring 1994, Raven Press, New York p. 21.
Moss et al., 1993, "Interaction of ADP-ribosylation factor with Escherichia coli enterotoxin that contains an inactivating lysine 112 substitution", J. Biol. Chem. 268(9):6383-6387.
Conner et al., 1993, "Rotavirus vaccine administered parenterally induces protective immunity", J. Virol. 67(11):6633-6641.
Santiago et al., 1993, "Oral immunization of rats with proteinoid microspheres encapsulating influenza virus antigens", Pharmaceutical Research 10(8):1243-1247.
Gould-Fogerite and Mannino, 1993, In: Liposome Technology, Second Edition, vol. III, Gregoriadis (ed.), CRC Press, Boca Raton pp. 261-276.
Clements et al., 1992, In: Recombinant DNA vaccines: Rationale and Strategy, Isaacson (ed.), Marcel Decker, New York pp. 293-321.
Cardenas and Clements, 1992, "Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens", Clin. Microbiol. Rev. 5(3):328-342.
Lycke et al., 1992, "The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity", Eur. J. Immunol. 22:2277-2281.
Garcon and Six, 1991, "Universal vaccine carrier: Liposomes that provide T-dependent help to weak antigens", J. Immunol. 146:3697-3702.
Mowat and Donachie, 1991 "ISCOMS--a novel strategy for mucosal immunization?", Immunol. Today 12(11):383-385.
Arai et al., 1990, "Cytokines: Coordinators of immune and inflammatory responses", Annu. Rev. Biochem. 59:783-836.
Clements and Cardenas, 1990, "Vaccines against enterotoxigenic bacterial pathogens based on hybrid Salmonella that express heterologous antigens", Res. Microbiol. 141:981-993.
Brandtzaeg, 1989, "Overview of the mucosal immune system", Curr. Top. Microbiol. Immunol. 146:13-25.
Elson, 1989, "Cholera toxin and its subunits as potential oral adjuvants", Curr. Topics Microbiol. Immunol. 146:29-33.
Liang et al., 1988, "Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus", J. Immunol. 141(5):1495-1501.
Clemens et al., 1988, "Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial", J. Infect. Dis. 158(2):372-377.
Clements et al., 1988, "Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens", Vaccine 6:269-277.
Clements et al., 1988, "Escherichia coli heat-labile enterotoxin possesses adjuvant activity and prevents the induction of oral tolerance in mice to unrelated protein antigens", Abstract No. B-91, 88th Ann. Meet. Am. Soc. Microbiol.
Alving et al., 1986, "Effectiveness of liposomes as potential carriers of vaccines: Applications to cholera toxin and human malaria sporozoite antigen", Vaccine 4:166-172.
Owen et al., 1986, "M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: A mechanism for antigen sampling and for microbial transepithelial migration", J. Infect. Dis. 153(6):1108-1118.
Lycke and Holmgren, 1986, "Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens", Immunology 59:301-308.
Cebra et al., 1986, In: Vaccines 86, Brown et al. (eds.), Cold Spring HArbor Laboratory, New York pp. 129-133.
Elson and Ealding, 1984, "Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen", J. Immunol. 133(6):2892-2897.
Clements and El-Morshidy, 1984, "Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas", Infect. Immun. 46(2):564-569.
Strober and Jacobs, 1985, In: Advances in host defense mechanisms, vol. 4., Mucosal Immunity, Gallin and Fauci (eds.), Raven Press, New York, pp. 1-30.
Tomasi and Plaut, 1985, In: Advances in host defense mechanisms, vol. 4., Mucosal Immunity, Gallin and Fauci (eds.), Raven Press, New York, pp. 31-61.
McKenzie and Halsey, 1984, Cholera toxin B subunit as a carrier protein to stimulate mucosal immune response, J. Immunol. 133(4):1818-1824.
Elson and Ealding, 1984, "Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin", J. Immunol. 132(6):2736-2741.
Svennerholm et al., 1984, "Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine", J. Infect. Dis. 149(6):884-893.
Pierce et al., 1983, "Procholeragenoid: A safe and effective antigen for oral immunization against experimental cholera", Infect. Immun. 40(3):1112-1118.
Clements et al., 1983, "Cloning and molecular characterization of the B subunit of Escherichia coli heat-labile enterotoxin", Infect. Immun. 40:653-658.
Dallas and Falkow, 1980, "Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin", Nature 228:499-501.
Clements et al., 1980, "Properties of homogenous heat-labile enterotoxin from Escherichia coli", Infect. Immun. 29:91-97.
Field, 1980, In: Secretory diarrhea, Field et al., (eds.) Waverly Press, Baltimore, pp. 21-30.
Clements and Finkelstein, 1979, "Isolation and characterization of homogenous heat-labile enterotoxins with high specific activity from Escherichia coli culture", Infect. Immun. 24:760-769.
Clements and Finkelstein, 1979, "Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli", Infect. Immun. 22:709-713.
Clements and Finkelstein, 1978, "Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin", Infect. Immun. 21:1036-1039.
Bockman and Cooper, 1973, "Pinocytosis by epithelium associated with lymphoid follicles in the bursa of fabricius, appendix, and Peyer's patches. An electron microscope study", Am. J. Anat. 136:455-477.
Finkelstein and LoSpalluto, 1969, "Pathogenesis of experimental cholera: Preparation and isolation of choleragen and choleragenoid", J. Exp. Med. 130:185-202.
Holmgren et al., 1993, Vaccine 11:1179-1184.
Lycke et al., 1992, Eur J Immunol 22:2277-2281.
Holmgren et al., 1994, Am J. Trop. Med Hyg 50:42-54.
Lai et al, Advances in Enzymology and Related Areas of Molecular Biology 58:99-140, 1986.
Holmgren et al, Vaccine 11(12):1179-1186, 1993.
Pizza et al. Molecular Microbiology 14(1):51-60, 1994.
Backstrom et al. Gene 149:211-217, 1994.
Williams et al. Journal of Biological Chemistry 265(33):20673-7, 1990.
Loosmor

Affiliated with

Also associated with

Rating

Mutant enterotoxin effective as a non-toxic oral adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mutant enterotoxin effective as a non-toxic oral adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant enterotoxin effective as a non-toxic oral adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-935233